SciELO - Scientific Electronic Library Online

 
vol.55 número2Parámetros y Tendencias Genéticas para Característica de Crecimiento Predestete en una Población Bovina Multirracial en ColombiaValoración del Estrés en Toros Brasileros y Venezolanos Mediante la Evaluación de las Concentraciones de Cortisol y el Recuento Leucocitario índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista de la Facultad de Ciencias Veterinarias

versión impresa ISSN 0258-6576

Resumen

GONZALEZ, María C; PEREZ, Nelson  y  BERMUDEZ, Víctor. Oil Inactivated Vaccine Development with Venezuelan Strain of Eastern Equine Encephalitis Virus. Rev. Fac. Cienc. Vet. [online]. 2014, vol.55, n.2, pp.78-87. ISSN 0258-6576.

The Pao of eastern encephalitis venezuelan isolated in 2002 (EE VE02 EL PAO) strain was used as an antigen to produce an inactivated oil vaccine against the Eastern Equine Encephalitis Virus (EEEV) in three formulations, as follows: Formulation I (F1): antigen in oil phase; Formulation II (F2): antigen in oil phase-maintenance medium; and Formulation III (F3): antigen-oil phase-antigen. The virus suspension was obtained from African green monkey kidney monolayer cell cultures. The binary ethylenimine (BEI) was used to inactivate the virus, along with an incomplete Freund´s adjuvant. The following quality control tests were performed: identity, viral load, sterility, physicochemical, safety, potency, immunity, and viability. All these tests were satisfactory. The administration to guinea pigs of a single subcutaneous dose of 1 mL of the formulations, caused stimulated antibody titers by hemagglutination inhibition (≥ 20) and serum neutralization (≥ 40), respectively, at 21 days post-vaccination. No statistically significant differences (P> 0.05) in the detection of antibodies between formulations at 21 days post-vaccination were observed, although F3 had higher titles, followed by F2 and F1, respectively (P<0.01). The antibodies neutralized EEEV virulent strains in vitro and the vaccinated guinea pigs did not develop viremia or neurological disease, when challenged with live virus, both intracerebrally and intraperitoneally in potency tests. It is concluded that the vaccine is safe and provides excellent protection against EEEV infection.

Palabras clave : Vaccine inactivate; equine encephalomyelitis virus; antibodies; quality controls; infectious diseases.

        · resumen en Español     · texto en Español     · Español ( pdf )